Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab

Natalizumab (NAT) was the first disease modifying therapy used for the treatment of relapsing-remitting multiple sclerosis (MS) that was designed with a specific mechanism of action that targets an important step of the MS immunopathology, directly blocking the T lymphocyte intrusion in the central...

Descripción completa

Detalles Bibliográficos
Autores principales: Maier, Smaranda, Simu, Mihaela, Hutanu, Adina, Barcutean, Laura, Voidazan, Septimiu, Bajko, Zoltan, Motataianu, Anca, Lata, Irina, Balasa, Rodica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692182/
https://www.ncbi.nlm.nih.gov/pubmed/33143271
http://dx.doi.org/10.3390/brainsci10110802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692182/
https://www.ncbi.nlm.nih.gov/pubmed/33143271
http://dx.doi.org/10.3390/brainsci10110802

Ejemplares similares